XIENCE V stent

Another sirolimus analogue, Everolimus, on cobalt chromium stent platform (XIENCE V stent, Abbott Laboratories, Abbott Park, Illinois), was compared to the TAXUS stent in the SPIRIT III trial and found to have better MACE rates. The XIENCE V is approved in Europe and is awaiting FDA approval. 

This dual use of polymers and a double-layered engineering strategy affects drug release parameters. The Xience V stent has been reported to release 25% of its total everolimus content on the first day after placement in the vascular bed, with the remaining 75% of drug released over 4 months, while most of the drug release remains in the local vascular microenvironment with minimal systemic release of the drug [5]. 

---